Hyperactivity: Glycogen synthase kinase-3 as a therapeutic target

The diagnosis of hyperactivity-associated disorders has increased within the past few years. The prevalence of hyperactivity-associated disorders is indicative of the need to more fully understand the underlying causes and to develop improved therapeutic interventions. There is increasing evidence t...

Full description

Saved in:
Bibliographic Details
Published in:European journal of pharmacology 2013-05, Vol.708 (1-3), p.56-59
Main Author: Mines, Marjelo A.
Format: Article
Language:English
Subjects:
Amphetamine
animal models
Animals
Attention-deficit/hyperactivity disorder
drugs
genetically modified organisms
glycogen
Glycogen Synthase Kinase 3 - physiology
Glycogen synthase-kinase 3
Humans
Hyperkinesis - enzymology
Hyperkinesis - etiology
Hyperkinesis - physiopathology
locomotion
Locomotor hyperactivity
rodents
Stimulants
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The diagnosis of hyperactivity-associated disorders has increased within the past few years. The prevalence of hyperactivity-associated disorders is indicative of the need to more fully understand the underlying causes and to develop improved therapeutic interventions. There is increasing evidence that glycogen synthase kinase-3 (GSK3) mediates locomotor hyperactivity in a number of animal models, and therefore may be a potential target for therapeutic intervention in hyperactivity-associated behaviors. In this review, we discuss 1) the effect of manipulations of GSK3 in the absence of drugs and disorders on locomotor activity, 2) the role of GSK3 in drug-induced hyperactivity in rodents, and 3) regulation of locomotor activity by GSK3 in transgenic mouse models related to specific disorders. These studies link GSK3 regulation and activity to hyperactivity-associated behaviors and disease pathologies.
ISSN:0014-2999
1879-0712
DOI:10.1016/j.ejphar.2013.02.055